Profile data is unavailable for this security.
About the company
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
- Revenue in USD (TTM)22.64m
- Net income in USD-34.12m
- Incorporated1988
- Employees76.00
- LocationDelcath Systems Inc566 Queensbury AvenueQUEENSBURY 12804United StatesUSA
- Phone+1 (518) 743-8892
- Fax+1 (212) 489-2102
- Websitehttps://delcath.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LifeMD Inc | 193.06m | -25.61m | 245.06m | 207.00 | -- | -- | -- | 1.27 | -0.6409 | -0.6409 | 4.85 | -0.1847 | 3.41 | 6.21 | 36.89 | 932,652.80 | -39.18 | -153.05 | -240.82 | -526.91 | 89.64 | 83.66 | -11.49 | -45.44 | 0.7805 | -8.83 | 1.49 | -- | 28.15 | 78.90 | 51.27 | -- | 143.64 | -- |
| Atlantic International Corp | 313.06m | -68.07m | 253.24m | 7.00 | -- | 14.11 | -- | 0.8089 | -5.55 | -5.55 | 12.45 | 0.358 | 4.44 | -- | 10.48 | 44,723,330.00 | -96.45 | -71.97 | -233.48 | -106.09 | 10.81 | 61.01 | -21.74 | -1,471.82 | -- | -1.64 | 0.8328 | -- | -100.00 | -- | -37.43 | -- | -- | -- |
| Pulmonx Corp | 79.30m | -57.11m | 253.51m | 279.00 | -- | 2.70 | -- | 3.20 | -1.47 | -1.47 | 2.04 | 2.38 | 0.45 | 1.24 | 7.29 | 284,236.60 | -32.41 | -26.27 | -36.42 | -28.97 | 74.16 | 71.95 | -72.01 | -93.76 | 6.77 | -- | 0.2839 | -- | 27.98 | 27.98 | -3.26 | -- | 20.62 | -- |
| Anika Therapeutics Inc | 164.17m | -97.52m | 255.27m | 357.00 | -- | 1.42 | -- | 1.55 | -6.64 | -6.64 | 11.14 | 12.24 | 0.5868 | 1.47 | 5.21 | 459,854.30 | -34.86 | -5.41 | -38.55 | -5.87 | 62.70 | 60.70 | -59.40 | -12.60 | 3.78 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Zynex Inc | 193.67m | 4.82m | 258.27m | 1.10k | 54.76 | 7.33 | 27.62 | 1.33 | 0.1481 | 0.1481 | 5.91 | 1.11 | 1.40 | 2.57 | 7.05 | 176,059.10 | 3.48 | 14.58 | 4.06 | 17.52 | 80.20 | 79.62 | 2.49 | 10.44 | 3.15 | 4.15 | 0.6246 | -- | 16.54 | 42.01 | -42.91 | 0.3741 | 2.19 | -- |
| Neuropace Inc | 76.45m | -28.09m | 268.63m | 171.00 | -- | 27.28 | -- | 3.51 | -0.9924 | -0.9924 | 2.70 | 0.3299 | 0.7817 | 1.83 | 6.69 | 447,087.70 | -28.72 | -- | -33.44 | -- | 73.83 | -- | -36.74 | -- | 4.77 | -4.06 | 0.8578 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
| AngioDynamics, Inc. | 292.73m | -243.03m | 282.41m | 748.00 | -- | 1.45 | -- | 0.9648 | -6.04 | -6.04 | 7.25 | 4.79 | 0.7434 | 2.27 | 6.55 | 391,344.90 | -61.72 | -16.38 | -74.39 | -18.70 | 51.71 | 52.95 | -83.02 | -30.49 | 1.41 | -- | 0.00 | -- | -10.28 | 2.35 | -251.53 | -- | 13.09 | -- |
| OraSure Technologies, Inc. | 224.26m | 11.37m | 287.19m | 638.00 | 25.57 | 0.6748 | 11.73 | 1.28 | 0.1506 | 0.1506 | 3.01 | 5.71 | 0.4862 | 2.64 | 5.58 | 351,509.40 | 2.72 | 0.7238 | 2.94 | 0.8212 | 42.26 | 46.94 | 5.59 | 1.13 | 11.20 | -- | 0.0004 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Clearpoint Neuro Inc | 30.43m | -18.15m | 305.91m | 107.00 | -- | 10.55 | -- | 10.05 | -0.6912 | -0.6912 | 1.16 | 1.05 | 0.7242 | 1.50 | 9.66 | 284,383.20 | -43.19 | -34.75 | -51.20 | -39.67 | 60.38 | 64.75 | -59.64 | -76.91 | 3.61 | -- | 0.00 | -- | 16.56 | 26.64 | -34.40 | -- | 75.30 | -- |
| Cerus Corp | 197.91m | -19.73m | 310.14m | 288.00 | -- | 5.80 | -- | 1.57 | -0.1076 | -0.1076 | 1.08 | 0.2882 | 1.00 | 1.97 | 7.88 | 687,194.40 | -10.01 | -25.99 | -15.26 | -40.62 | 60.52 | 61.90 | -10.00 | -35.81 | 1.92 | -1.19 | 0.6057 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Delcath Systems Inc | 22.64m | -34.12m | 314.94m | 76.00 | -- | 32.20 | -- | 13.91 | -1.36 | -1.36 | 0.8343 | 0.3059 | 0.5714 | 0.9094 | 6.34 | 297,947.40 | -86.11 | -116.57 | -156.17 | -243.21 | 81.31 | 71.02 | -150.70 | -1,235.37 | 1.03 | -172.60 | 0.1892 | -- | -24.05 | -9.53 | -30.60 | -- | -5.26 | -- |
| CVRx Inc | 47.26m | -58.48m | 358.37m | 200.00 | -- | 5.48 | -- | 7.58 | -2.71 | -2.71 | 2.19 | 2.69 | 0.4038 | 0.657 | 6.14 | 236,275.00 | -49.96 | -- | -54.21 | -- | 84.16 | -- | -123.75 | -- | 10.23 | -17.04 | 0.4302 | -- | 74.89 | -- | 0.5528 | -- | -- | -- |
| Nano-X Imaging Ltd | 10.13m | -57.47m | 360.34m | 164.00 | -- | 2.06 | -- | 35.58 | -0.9974 | -0.9974 | 0.1755 | 2.99 | 0.0482 | -- | 6.89 | 61,756.10 | -27.33 | -30.98 | -29.96 | -35.10 | -81.80 | -- | -567.41 | -1,527.24 | 5.09 | -- | 0.0181 | -- | 15.47 | -- | 46.33 | -- | 114.35 | -- |
| MaxCyte Inc | 45.60m | -35.74m | 363.91m | 143.00 | -- | 1.70 | -- | 7.98 | -0.3420 | -0.3420 | 0.4368 | 2.03 | 0.177 | 0.5576 | 7.17 | 318,878.30 | -13.87 | -13.18 | -14.86 | -14.33 | 85.98 | 88.79 | -78.37 | -62.96 | 9.22 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| ZimVie Inc | 451.30m | -47.73m | 379.21m | 2.60k | -- | 0.9321 | -- | 0.8403 | -1.77 | -13.16 | 16.60 | 14.74 | 0.394 | 1.14 | 4.04 | 173,575.00 | -4.17 | -- | -4.81 | -- | 63.18 | 65.51 | -10.58 | -8.73 | 1.38 | -0.6264 | 0.3514 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
| Tactile Systems Technology Inc | 285.05m | 15.45m | 382.51m | 992.00 | 24.79 | 1.84 | 17.27 | 1.34 | 0.643 | 0.643 | 11.91 | 8.66 | 0.9812 | 6.20 | 6.80 | 287,349.80 | 5.32 | 0.9015 | 6.20 | 1.09 | 51.44 | 49.10 | 5.42 | 0.8309 | 3.80 | -- | 0.1146 | 0.00 | 11.20 | 13.81 | 259.60 | 33.91 | -23.62 | -- |
Data as of Nov 22 2024. Currency figures normalised to Delcath Systems Inc's reporting currency: US Dollar USD
31.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rosalind Advisors, Inc.as of 30 Sep 2024 | 2.65m | 12.02% |
| AIGH Capital Management LLCas of 05 Nov 2024 | 1.47m | 6.68% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.10m | 5.00% |
| Essex Investment Management Co. LLCas of 30 Sep 2024 | 336.72k | 1.53% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 311.80k | 1.41% |
| Geode Capital Management LLCas of 30 Sep 2024 | 251.90k | 1.14% |
| Millennium Management LLCas of 30 Sep 2024 | 205.11k | 0.93% |
| CIBC World Markets, Inc.as of 30 Sep 2024 | 200.49k | 0.91% |
| Polar Asset Management Partners, Inc.as of 30 Sep 2024 | 176.50k | 0.80% |
| Avenue Capital Management II LPas of 30 Sep 2024 | 161.83k | 0.73% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
